BSH 2023 | Rilzabrutinib: a novel promising BTK inhibitor being explored in ITP

David Kuter • 24 Apr 2023

BSH 2023

In this video, David Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA, discusses data from a recent Phase I/II clinical study (NCT03395210) evaluating the use of rilzabrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor, to treat patients with immune thrombocytopenia (ITP). Prof. Kuter briefly describes the mechanism of action of BTK inhibitors and highlights promising results from the study. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research: Alnylam, Biocryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UCB

Consulting: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui. Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Platelet Disorder Support Association, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia). Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen

Stock ownership: Rubius